ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

Company Overview - ProSomnus, Inc. is the leading non-CPAP therapy for Obstructive Sleep Apnea (OSA), a condition affecting over 1 billion people globally [2] - The company's intraoral medical devices are designed to track treatment plans and patient anatomy precisely, demonstrating excellent efficacy, safety, and adherence [2] - ProSomnus devices are FDA-cleared, patented, and covered by various insurance plans, representing over 200 million covered lives [2] Recent Developments - The company has postponed the release of its 2023 fourth quarter and full year financial results, with the new date set for March 26, 2024 [1] - An investor conference call will take place after market close on the same day, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] - ProSomnus will not be attending the Roth Conference [1]